uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell”

uniQure (NASDAQ:QURE) was upgraded by StockNews.com to a “sell” rating in a research report issued to clients and investors on Thursday.

QURE has been the topic of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of uniQure in a research report on Friday, September 20th. The Goldman Sachs Group increased their price target on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Tuesday, August 20th. Finally, Raymond James reissued an “outperform” rating and set a $20.00 price target on shares of uniQure in a research report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, uniQure currently has an average rating of “Hold” and an average target price of $19.50.

uniQure Stock Performance

Shares of uniQure stock opened at $6.47 on Thursday. The stock’s fifty day moving average is $5.80 and its two-hundred day moving average is $5.65. The company has a market capitalization of $314.11 million, a PE ratio of -1.04 and a beta of 0.95. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. uniQure has a 52 week low of $3.73 and a 52 week high of $11.35.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.08. The company had revenue of $11.13 million for the quarter, compared to the consensus estimate of $3.47 million. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. As a group, analysts expect that uniQure will post -4.04 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Acadian Asset Management LLC raised its stake in uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares during the last quarter. Ikarian Capital LLC raised its stake in uniQure by 198.1% in the first quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock valued at $2,439,000 after buying an additional 311,768 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in uniQure in the second quarter valued at about $815,000. Privium Fund Management B.V. raised its stake in uniQure by 30.3% in the first quarter. Privium Fund Management B.V. now owns 578,915 shares of the biotechnology company’s stock valued at $3,010,000 after buying an additional 134,767 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after buying an additional 109,740 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.